Group | Excellent (score 5) | Good (score 4) | Average (score 3) | Acceptable (score 2) | Non-diagnostic (score 1) | Average score |
---|---|---|---|---|---|---|
Exploration cohort | ||||||
G1 (n = 46) | 0 | 0 | 0 | 44 (95.7%) | 2 (4.3%) | 2.0 ± 0.2* |
G2 (n = 46) | 0 | 0 | 40 (87.0%) | 6 (13.0%) | 0 | 2.9 ± 0.3* |
G3 (n = 46) | 0 | 0 | 46 (100%) | 0 | 0 | 3.0 ± 0.0* |
G5 (n = 46) | 0 | 43 (93.5%) | 3 (6.5%) | 0 | 0 | 3.9 ± 0.2* |
G8 (n = 46) | 10 (11.7%) | 36 (78.3%) | 0 | 0 | 0 | 4.2 ± 0.4* |
Clinical validation cohort | ||||||
G2† (n = 147) | 0 | 0 | 143 (97.3%) | 4 (2.7%) | 0 | 3.0 ± 0.2* |
G3† (n = 147) | 0 | 1 (0.7%) | 146 (99.3%) | 0 | 0 | 3.0 ± 0.1* |
G5† (n = 147) | 0 | 85 (57.8%) | 62 (42.2%) | 0 | 0 | 3.6 ± 0.5* |
G8† (n = 147) | 8 (5.4%) | 134 (91.2%) | 5 (3.4%) | 0 | 0 | 4.0 ± 0.3* |
Gs† (n = 147) | 63 (42.9%) | 84 (57.1%) | 0 | 0 | 0 | 4.4 ± 0.5* |